251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus. (April 2019)

• Record Type: Journal Article
• Authors: Jordan, Jarrat; Sweet, Kristen; Cesaroni, Matteo; Ma, Keying; Franks, Carol; Seridi, Loqmane; Schreiter, Jessica; Gordon, Robert; Lipsky, Peter; Vollenhoven, Ronald van; Tsokos, George C; Hahn, Bevra H; Rose, Shawn; Baribaud, Frédéric; Loza, Matthew J; Campbell, Kim
• Is Part Of: Lupus science & medicine. Volume 6(2019)supplement 1
• Page Start: A185
• Page End: A185
• Publication Date: 2019-04
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2019-lsm.251
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Background: Treatment with ustekinumab (UST), an anti-IL-12/23, p40-neutralizing monoclonal antibody, improved global and organ-specific measures of disease activity in a randomized, placebo (PBO)-controlled trial of patients with active SLE (NCT02349061 ). 1 Type I interferon (IFN-I) and type II IFN (IFN-gamma) are elevated in a subset of SLE patients. Although targeting IFN-I (anifrolumab) has demonstrated inconsistent efficacy and a preliminary study with anti-IFN-gamma mAb (AMG811) failed to establish benefit, 2 3 we sought to determine if UST affects either pathway and if those effects correlated with a positive SRI-4 response at wk24. Methods: A phase-2, PBO-controlled study enrolled 102 adults with seropositive SLE (SLICC criteria) and active disease (baseline SLEDAI score 6 and 1 BILAG A and/or 2 BILAG B scores) despite standard-of-care therapy. 1 Gene expression analysis using a 21 gene IFN-I gene signature (IGS) 4 or IFN-gamma signature 5 was performed by microarray analysis using whole blood PAXgene RNA samples. Serum IFN-gamma and IFN- levels were assessed using MSD (IFN-gamma) and Quanterix (IFN-). Results: Serum IFN-gamma and IFN- and the IGS were elevated at baseline in SLE compared to healthy controls (p<0.0001). IGS was increased in approximately 67% of the SLE patients at baseline. No decrease was observed with IFN- protein or IGS levels after treatment with either UST or PBO. Whereas the proportion of patients achieving an SRI-4 response at wk24 was numerically greater in the IGS low patients (81.8% UST vs. 54.5% PBO) versus IGS high (48.6% UST vs. 20% PBO), the magnitude of the treatment effect (UST vs. PBO) was similar in both subsets (IGS low effect size=27.3% vs. IGS high effect size=28.6%). Despite similar baseline levels, UST-treated patients achieving an SRI-4 response at wk24 exhibited a significant decrease in IFN-gamma protein versus non-responders (p<0.05) at 4 and 8 wks and IFN-gamma gene signature at 4 wks (p<0.0001) and 24 wks (p<0.05) post-dosing. Conclusions: In this SLE trial population which had significant upregulation of IFN-I at baseline, clinical response to UST was not associated with IFN-I reduction. In contrast, a significant decrease in IFN-gamma protein and gene signature was associated with UST response. These findings suggest that a broad population of SLE patients may respond to UST regardless of baseline IFN-I status. Moreover, UST may have affected TH1 responses in SLE since IFN-gamma levels decreased following treatment. Funding Source(s): Janssen Research and Development, LLC supported this study References: VanVollenhoven RF. Lancet 2018;392:1330. Furie R. Arthritis Rheumatol 2017;69:376. Boedigheimer MJ. Lupus Sci Med 2017;4:e000226. Yao Y. Human Genomics Proteomics 2009. doi:10.4061/2009/374312 Welcher AA. Arthritis & Rheumatol 2015;67:2713.